Monash University has announced a new drug that can beat the cholesterol that increases the risk of Cardiac arrest and stroke. The Lipoprotein(a) is a genetic form of cholesterol that has a serious impact. Currently, there is no treatment for this in the market. This groundbreaking discovery is the world’s first medication for the Lipoprotein(a) cholesterol type. Let’s have a closer look at the study and its findings.
Research Study and Findings
Director of the Victorian Heart Institute and Victorian Heart Hospital at Monash University, Professor Stephen Nicholls led the remarkable study. The New oral drug ‘Muvalaplin‘ demonstrated incredible success in the trial for treating Lipoprotein(a). It effectively lowers the cholesterol level by up to 65%.
“This drug is a game-changer in more ways than one. Not only do we have an option for lowering an elusive form of cholesterol, but being able to deliver it in an oral tablet means it will be more accessible to patients,” says Professor Stephen Nicholls.
The Muvalaplin drug disrupts the formation of the Lipoprotein(a) or Lp(a) cholesterol type in the body. Lp(a) has a similarity to LDL cholesterol. But even the common LDL-lowering drugs are not working against it. Since Lp(a) is largely genetic, diet and exercise can’t completely control the formation of Lp(a). Therefore the New drug has a miraculous impact in reducing the risk of cardiovascular diseases.
The global research industry has been working on a solution to treat Lp(a) for over 10 years. It is often referred to as a ‘silent killer’ with no proper medication. This new drug changes that going forward. The breakthrough findings are presented at the European Society of Cardiology Congress in Amsterdam and published in JAMA.
“When it comes to treating high Lp(a), a known risk factor for cardiovascular disease, our clinicians currently have no effective tools in their kit,” says Professor Stephen Nicholls.
Conclusion
Monash University has announced a new drug that can beat the cholesterol that increases the risk of Cardiac arrest and stroke. It is often referred to as a ‘silent killer’ with no proper medication. The Lipoprotein(a) is a genetic form of cholesterol that has a serious impact. Currently, there is no treatment for this in the market. The New oral drug ‘Muvalaplin’ is the world’s first medication for the Lipoprotein(a) cholesterol type.
Journal Reference;
“Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation” by Stephen J. Nicholls, Steven E. Nissen, Cynthia Fleming, Shweta Urva, Jeffrey Suico, Paul H. Berg, Helle Linnebjerg, Giacomo Ruotolo, P. Kellie Turner and Laura F. Michael, 28 August 2023, JAMA.
DOI: 10.1001/jama.2023.16503
Also read,
- New Study Shows A Promise in Treating Diabetes And Obesity!
- A Scientific Breakthrough In Treating Alcohol Addiction!
